Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
April Dogs Of The Dow: One To Buy
Published: March 31, 2026 by: Seeking Alpha
Sentiment: Positive
Verizon (VZ) is the only Dow stock in April 2026 meeting the ideal of annual dividends from $1K invested exceeding its share price, supported by robust free cash flow. Analyst forecasts suggest the top ten Dow dividend stocks could deliver average net gains of 45.76% by April 2027, albeit with above-market volatility. Dividend dogcatcher strategy prioritizes stocks where dividends from $1K invested surpass share price; currently, only VZ qualifies, but more may reach this on market pullbacks.
Read More
Merck's drug reduced bad cholesterol by 64.6% in late-stage trial
Published: March 30, 2026 by: Reuters
Sentiment: Positive
Merck's oral drug reduced bad cholesterol by 64.6% in a late-stage trial, it said on Monday, as the company looks for its next blockbuster candidate.
Read More
How Merck's New Cholesterol Buster Will 'Move The Needle' 'By Removing The Needle'
Published: March 30, 2026 by: Investors Business Daily
Sentiment: Positive
Merck's experimental cholesterol buster easily outperformed a triplet of medications, the Dow Jones component said Monday.
Read More
Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Published: March 30, 2026 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non-Statin Therapies.
Read More
Can MRK's Ongoing M&A Push Aid Long-Term Growth Ahead of Keytruda LOE?
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Merck's recent M&A spree, including its $6.7B Terns deal, aims to diversify its pipeline and revenue base as Keytruda nears its 2028 exclusivity loss.
Read More
Merck Stock Soars 50% in 6 Months: Buy, Hold, or Take Profits?
Published: March 27, 2026 by: Zacks Investment Research
Sentiment: Neutral
MRK stock has surged over 50% in six months, but looming patent risks and weak vaccine sales raise questions on whether investors should hold or trim.
Read More
Merck & Co., Inc. (MRK) M&A Call Transcript
Published: March 25, 2026 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (MRK) M&A Call Transcript
Read More
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Published: March 25, 2026 by: Benzinga
Sentiment: Neutral
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Read More
Merck to acquire Terns Pharmaceuticals for $6.7B
Published: March 25, 2026 by: Proactive Investors
Sentiment: Positive
Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals (NASDAQ:TERN) for $53 per share in cash, valuing the company at approximately $6.7 billion. This marks Merck's third multibillion-dollar acquisition in the past year as the company looks to strengthen its portfolio ahead of its top-selling cancer drug Keytruda losing patent protection in 2028.
Read More
J&J or Merck? Key Factors Investors Must Weigh Right Now
Published: March 18, 2026 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson JNJ and Merck MRK are among the top U.S. healthcare giants, making them ideal candidates for a direct comparison.
Read More
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?
Published: March 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
Read More
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Most Retirees Overlook These Dow Dividend Stocks — They Pay More Than You'd Expect
Published: March 03, 2026 by: 24/7 Wall Street
Sentiment: Positive
The Dow Jones Industrial Average, commonly just called the Dow Jones or the Dow, includes 30 giant publicly listed companies with U.S.
Read More
Merck's Keytruda Drives its 2025 Revenue Surge: What's Ahead?
Published: March 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Merck MRK has a strong foothold in the oncology market, primarily supported by its biggest revenue driver, Keytruda. The blockbuster PD-1 inhibitor accounts for around 55% of the company's pharmaceutical sales and has played an instrumental role in driving Merck's steady revenue growth over the past few years.
Read More
Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Published: February 27, 2026 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) reduced the risk of event-free survival (EFS) events by 47% and reduced the risk of death by 35% when given before and after surgery versus neoadjuvant chemotherapy and surgery in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. These late-breaking data will.
Read More
Merck Stock Jumps But Reddit Traders Are Getting Cold Feet
Published: February 26, 2026 by: 24/7 Wall Street
Sentiment: Positive
A giant in the healthcare space, Merck ( NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a neutral 43 this week.
Read More
Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.
Published: February 25, 2026 by: Barrons
Sentiment: Positive
Merck's two-drug HIV regimen matched Gilead's blockbuster Biktarvy in Phase 3 trials and is under FDA review as the company prepares for Keytruda's patent cliff.
Read More
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Read More
Merck creates separate oncology arm ahead of Keytruda patent loss
Published: February 23, 2026 by: Invezz
Sentiment: Neutral
Merck said on Monday that it will split its human-health operations into two separate divisions, a move designed to sharpen focus across its portfolio and ensure smoother launches of new medicines. The move comes as the drugmaker seeks to prepare for mounting sales pressure later this decade, driven by the looming loss of exclusivity for its top-selling cancer drug Keytruda, which will also expose it to lower-cost copycat competition.
Read More
Merck reportedly ready to the splits as Keytruda patent cliff looms. Market shrugs
Published: February 23, 2026 by: Proactive Investors
Sentiment: Neutral
Investors gave a collective meh to news that Merck & Co Inc (NYSE:MRK, XETRA:6MK) is reportedly restructuring its human-health division, with shares marking time in premarket trading despite a reorganisation that signals the US drugmaker is bracing for the biggest revenue hit in its recent history. The Wall Street Journal reported on Monday that Merck plans to separate its human-health operations into two distinct divisions.
Read More
Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.
Published: February 23, 2026 by: Barrons
Sentiment: Positive
The drug maker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.
Read More
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Evolves Human Health Operating Structure to Support Portfolio Execution.
Read More
Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports
Published: February 23, 2026 by: Reuters
Sentiment: Positive
Drugmaker Merck is separating its human-health business into two divisions to offset pressures related to the patent loss of its top-selling drug Keytruda, the Wall Street Journal reported on Monday.
Read More
Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.
Published: February 23, 2026 by: WSJ
Sentiment: Positive
The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.
Read More
Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
The pharmaceutical giant is finding ways to navigate despite headwinds. This has helped the shares outperform the market over the past year.
Read More
Could Merck Stock Quietly Help Turn Steady Dividends Into a Millionaire Retirement?
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
Merck is one of the world's largest drug companies. Although it isn't a player in the GLP-1 space, it has a well-supported dividend and a proven track record of dividend growth.
Read More
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Negative
BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.
Read More
Merck Indicates Better Growth Visibility in Post-Keytruda LOE Period
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Positive
MRK outlines solid long-term outlook with more than $70B opportunity beyond Keytruda LOE, backed by pipeline progress, new product launches and M&A deals.
Read More
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Published: February 16, 2026 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exceptional Corporate Resilience profile and attractive sustainability opportunity set in areas like the Digital Infrastructure build-out. Oracle stands out with a strong sustainability profile, offering notable opportunities in Digital Infrastructure, Education and the development of Enhanced Skills & Innovation.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert Davis
- Employees 73000